Search

Your search keyword '"Fong, Siew‐Wai"' showing total 175 results
Start Over Author "Fong, Siew‐Wai"
175 results on '"Fong, Siew‐Wai"'

1. Longitudinal single cell atlas identifies complex temporal relationship between type I interferon response and COVID-19 severity

Author

Lin, Quy Xiao Xuan, Rajagopalan, Deepa, Gamage, Akshamal M., Tan, Le Min, Venkatesh, Prasanna Nori, Chan, Wharton O. Y., Kumar, Dilip, Agrawal, Ragini, Chen, Yao, Fong, Siew-Wai, Singh, Amit, Sun, Louisa J., Tan, Seow-Yen, Chai, Louis Yi Ann, Somani, Jyoti, Lee, Bernett, Renia, Laurent, Ng, Lisa F P, Ramanathan, Kollengode, Wang, Lin-Fa, Young, Barnaby, Lye, David, Singhal, Amit, and Prabhakar, Shyam

Published
2024
Full Text
View/download PDF

2. Author Correction: Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave

Author

Goh, Yun Shan, Fong, Siew-Wai, Tay, Matthew Zirui, Rouers, Angeline, Chang, Zi Wei, Chavatte, Jean-Marc, Hor, Pei Xiang, Loh, Chiew Yee, Huang, Yuling, Tan, Yong Jie, Wang, Bei, Ngoh, Eve Zi Xian, Mohd Salleh, Siti Nazihah, Lee, Raphael Tze Chuen, Lim, Georgina, Maurer-Stroh, Sebastian, Wang, Cheng-I, Leo, Yee‐Sin, Lin, Raymond T. P., Lam, Meng Chon, Lye, David C., Young, Barnaby Edward, Ng, Lisa F. P., and Renia, Laurent

Published
2024
Full Text
View/download PDF

4. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial

Author

Poh, Xuan Ying, Torres-Ruesta, Anthony, Yoong, Terence, Wong, Nathan, Tan, Chee Wah, Rouers, Angeline, Chavatte, Jean-Marc, Goh, Yun Shan, Rao, Suma, Chia, Po Ying, Ong, Sean W.X., Lee, Tau Hong, Sadarangani, Sapna P., Lin, Ray J.H., Neo, Vanessa, Kam, Isaac Kai Jie, Huang, Yuling, Hor, Pei Xiang, Loh, Chiew Yee, Yeoh, Aileen Ying-Yan, Lim, Daniel R.X., Chia, Wanni, Ren, Ee Chee, Lin, Raymond T.P., Fong, Siew-Wai, Renia, Laurent, Lye, David Chien, Wang, Lin-Fa, Ng, Lisa F.P., and Young, Barnaby E.

Published
2024
Full Text
View/download PDF

6. First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial

Author

Poh, Xuan Ying, Lee, I. Russel, Tan, Chee Wah, Chavatte, Jean-Marc, Fong, Siew Wai, Goh, Yun Shan, Rouers, Angeline, Wong, Nathan, Torres-Ruesta, Anthony, Mah, Shirley Y.Y., Yeoh, Aileen Y.Y., Gandhi, Mihir, Rahman, Nabilah, Chin, Yi Qing, Lim, J. Jonathan, Yoong, Terence J.K., Rao, Suma, Chia, Po Ying, Ong, Sean W.X., Lee, Tau Hong, Sadarangani, Sapna P., Lin, Ray J.H., Lim, Daniel R.X., Chia, Wanni, Renia, Laurent, Ren, Ee Chee, Lin, Raymond T.P., Lye, David C., Wang, Lin-Fa, Ng, Lisa F.P., and Young, Barnaby E.

Published
2024
Full Text
View/download PDF

7. Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave

Author

Goh, Yun Shan, Fong, Siew-Wai, Tay, Matthew Zirui, Rouers, Angeline, Chang, Zi Wei, Chavatte, Jean-Marc, Hor, Pei Xiang, Loh, Chiew Yee, Huang, Yuling, Tan, Yong Jie, Wang, Bei, Ngoh, Eve Zi Xian, Mohd Salleh, Siti Nazihah, Lee, Raphael Tze Chuen, Lim, Georgina, Maurer-Stroh, Sebastian, Wang, Cheng-I, Leo, Yee‐Sin, Lin, Raymond T. P., Lam, Meng Chon, Lye, David C., Young, Barnaby Edward, Ng, Lisa F. P., and Renia, Laurent

Published
2023
Full Text
View/download PDF

9. Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Δ382 Variant Infection

Author

Fong, Siew-Wai, Yeo, Nicholas Kim-Wah, Chan, Yi-Hao, Goh, Yun Shan, Amrun, Siti Naqiah, Ang, Nicholas, Rajapakse, Menaka Priyadharsani, Lum, Josephine, Foo, Shihui, Lee, Cheryl Yi-Pin, Carissimo, Guillaume, Chee, Rhonda Sin-Ling, Torres-Ruesta, Anthony, Tay, Matthew Zirui, Chang, Zi Wei, Poh, Chek Meng, Young, Barnaby Edward, Tambyah, Paul A., Kalimuddin, Shirin, Leo, Yee-Sin, Lye, David C., Lee, Bernett, Biswas, Subhra, Howland, Shanshan Wu, Renia, Laurent, and Ng, Lisa F. P.

Published
2022
Full Text
View/download PDF

10. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

Author

Renia, Laurent, Goh, Yun Shan, Rouers, Angeline, Le Bert, Nina, Chia, Wan Ni, Chavatte, Jean-Marc, Fong, Siew‐Wai, Chang, Zi Wei, Zhuo, Nicole Ziyi, Tay, Matthew Zirui, Chan, Yi-Hao, Tan, Chee Wah, Yeo, Nicholas Kim‐Wah, Amrun, Siti Naqiah, Huang, Yuling, Wong, Joel Xu En, Hor, Pei Xiang, Loh, Chiew Yee, Wang, Bei, Ngoh, Eve Zi Xian, Salleh, Siti Nazihah Mohd, Carissimo, Guillaume, Dowla, Samanzer, Lim, Alicia Jieling, Zhang, Jinyan, Lim, Joey Ming Er, Wang, Cheng-I., Ding, Ying, Pada, Surinder, Sun, Louisa Jin, Somani, Jyoti, Lee, Eng Sing, Ong, Desmond Luan Seng, Leo, Yee‐Sin, MacAry, Paul A., Lin, Raymond Tzer Pin, Wang, Lin-Fa, Ren, Ee Chee, Lye, David C., Bertoletti, Antonio, Young, Barnaby Edward, and Ng, Lisa F. P.

Published
2022
Full Text
View/download PDF

11. Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study

Author

Young, Barnaby E, Wei, Wycliffe E, Fong, Siew-Wai, Mak, Tze-Minn, Anderson, Danielle E, Chan, Yi-Hao, Pung, Rachael, Heng, Cheryl SY, Ang, Li Wei, Zheng, Adrian Kang Eng, Lee, Bernett, Kalimuddin, Shirin, Pada, Surinder, Tambyah, Paul A, Parthasarathy, Purnima, Tan, Seow Yen, Sun, Louisa, Smith, Gavin JD, Lin, Raymond Tzer Pin, Leo, Yee-Sin, Renia, Laurent, Wang, Lin-Fa, Ng, Lisa FP, Maurer-Stroh, Sebastian, Lye, David Chien, and Lee, Vernon J

Published
2021
Full Text
View/download PDF

12. Variant-Specific IgA Protects Against Omicron Infection.

Author

Goh, Yun Shan, Fong, Siew-Wai, Hor, Pei Xiang, Loh, Chiew Yee, Wang, Bei, Salleh, Siti Nazihah Mohd, Ngoh, Eve Zi Xian, Lee, Raphael Tze Chuen, Poh, Xuan Ying, Rao, Suma, Chia, Po Ying, Ong, Sean W X, Lee, Tau Hong, Lim, Clarissa, Teo, Jefanie, Pada, Surinder, Sun, Louisa Jin, Ong, Desmond Luan Seng, Somani, Jyoti, and Lee, Eng Sing

Subjects
*SARS-CoV-2, *BREAKTHROUGH infections, *SARS-CoV-2 Omicron variant, *BOOSTER vaccines, *ANTIBODY formation
Abstract

Background The emergence of rapidly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, coupled with waning vaccine-induced immunity, has contributed to the rise of vaccine breakthrough infections. It is crucial to understand how vaccine-induced protection is mediated. Methods We examined 2 prospective cohorts of mRNA vaccinated and boosted individuals during the Omicron wave of infection in Singapore. Results We found that individuals who remain uninfected over the follow-up period had a higher variant-specific IgA, but not IgG, antibody response at 1 month after booster vaccination, compared with individuals who became infected. Conclusions We conclude that IgA may have a potential contributory role in protection against Omicron infection. Clinical Trials Registration. NCT05142319. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Decreased memory B cell frequencies in COVID‐19 delta variant vaccine breakthrough infection

Author

Tay, Matthew Zirui, Rouers, Angeline, Fong, Siew‐Wai, Goh, Yun Shan, Chan, Yi‐Hao, Chang, Zi Wei, Xu, Weili, Tan, Chee Wah, Chia, Wan Ni, Torres‐Ruesta, Anthony, Amrun, Siti Naqiah, Huang, Yuling, Hor, Pei Xiang, Loh, Chiew Yee, Yeo, Nicholas Kim‐Wah, Wang, Bei, Ngoh, Eve Zi Xian, Salleh, Siti Nazihah Mohd, Chavatte, Jean‐Marc, Lim, Alicia Jieling, Maurer‐Stroh, Sebastian, Wang, Lin‐Fa, Lin, Raymond Valentine Tzer Pin, Wang, Cheng‐I, Tan, Seow‐Yen, Young, Barnaby Edward, Leo, Yee‐Sin, Lye, David C, Renia, Laurent, and Ng, Lisa FP

Published
2022
Full Text
View/download PDF

15. Correction to: Robust Virus‐Specific Adaptive Immunity in COVID‐19 Patients with SARS‐CoV‐2 Δ382 Variant Infection

Author

Fong, Siew‐Wai, Yeo, Nicholas Kim‐Wah, Chan, Yi‐Hao, Goh, Yun Shan, Amrun, Siti Naqiah, Ang, Nicholas, Rajapakse, Menaka Priyadharsani, Lum, Josephine, Foo, Shihui, Lee, Cheryl Yi‐Pin, Carissimo, Guillaume, Chee, Rhonda Sin‐Ling, Torres‐Ruesta, Anthony, Tay, Matthew Zirui, Chang, Zi Wei, Poh, Chek Meng, Young, Barnaby Edward, Tambyah, Paul A., Kalimuddin, Shirin, Leo, Yee‐Sin, Lye, David C., Lee, Bernett, Biswas, Subhra, Howland, Shanshan Wu, Renia, Laurent, and Ng, Lisa F. P.

Published
2022
Full Text
View/download PDF

16. Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1)

Author

Goh, Yun Shan, Fong, Siew‐Wai, Hor, Pei Xiang, Loh, Chiew Yee, Tay, Matthew Zirui, Wang, Bei, Salleh, Siti Nazihah Mohd, Ngoh, Eve Zi Xian, Lee, Raphael Tze Chuen, Poh, Xuan Ying, Lee, I. Russel, Rao, Suma, Chia, Po Ying, Maurer-Stroh, Sebastian, Wang, Cheng-I, Leo, Yee‐Sin, Lye, David C., Young, Barnaby Edward, Ng, Lisa F.P., and Renia, Laurent

Published
2024
Full Text
View/download PDF

17. Asymptomatic COVID‐19: disease tolerance with efficient anti‐viral immunity against SARS‐CoV‐2

Author

Chan, Yi‐Hao, Fong, Siew‐Wai, Poh, Chek‐Meng, Carissimo, Guillaume, Yeo, Nicholas Kim‐Wah, Amrun, Siti Naqiah, Goh, Yun Shan, Lim, Jackwee, Xu, Weili, Chee, Rhonda Sin‐Ling, Torres‐Ruesta, Anthony, Lee, Cheryl Yi‐Pin, Tay, Matthew Zirui, Chang, Zi Wei, Lee, Wen‐Hsin, Wang, Bei, Tan, Seow‐Yen, Kalimuddin, Shirin, Young, Barnaby Edward, Leo, Yee‐Sin, Wang, Cheng‐I, Lee, Bernett, Rötzschke, Olaf, Lye, David Chien, Renia, Laurent, and Ng, Lisa F P

Published
2021
Full Text
View/download PDF

18. Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19

Author

Carissimo, Guillaume, Xu, Weili, Kwok, Immanuel, Abdad, Mohammad Yazid, Chan, Yi-Hao, Fong, Siew-Wai, Puan, Kia Joo, Lee, Cheryl Yi-Pin, Yeo, Nicholas Kim-Wah, Amrun, Siti Naqiah, Chee, Rhonda Sin-Ling, How, Wilson, Chan, Stephrene, Fan, Bingwen Eugene, Andiappan, Anand Kumar, Lee, Bernett, Rötzschke, Olaf, Young, Barnaby Edward, Leo, Yee-Sin, Lye, David Chien, Renia, Laurent, Ng, Lai Guan, Larbi, Anis, and Ng, Lisa FP

Published
2020
Full Text
View/download PDF

19. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Author

Poh, Chek Meng, Carissimo, Guillaume, Wang, Bei, Amrun, Siti Naqiah, Lee, Cheryl Yi-Pin, Chee, Rhonda Sin-Ling, Fong, Siew-Wai, Yeo, Nicholas Kim-Wah, Lee, Wen-Hsin, Torres-Ruesta, Anthony, Leo, Yee-Sin, Chen, Mark I-Cheng, Tan, Seow-Yen, Chai, Louis Yi Ann, Kalimuddin, Shirin, Kheng, Shirley Seah Gek, Thien, Siew-Yee, Young, Barnaby Edward, Lye, David C., Hanson, Brendon John, Wang, Cheng-I, Renia, Laurent, and Ng, Lisa F. P.

Published
2020
Full Text
View/download PDF

20. Crosstalk between CD64+MHCII+ macrophages and CD4+ T cells drives joint pathology during chikungunya.

Author

Lum, Fok-Moon, Chan, Yi-Hao, Teo, Teck-Hui, Becht, Etienne, Amrun, Siti Naqiah, Teng, Karen WW, Hartimath, Siddesh V, Yeo, Nicholas KW, Yee, Wearn-Xin, Ang, Nicholas, Torres-Ruesta, Anthony M, Fong, Siew-Wai, Goggi, Julian L, Newell, Evan W, Renia, Laurent, Carissimo, Guillaume, and Ng, Lisa FP

Abstract

Communications between immune cells are essential to ensure appropriate coordination of their activities. Here, we observed the infiltration of activated macrophages into the joint-footpads of chikungunya virus (CHIKV)-infected animals. Large numbers of CD64+MHCII+ and CD64+MHCII- macrophages were present in the joint-footpad, preceded by the recruitment of their CD11b+Ly6C+ inflammatory monocyte precursors. Recruitment and differentiation of these myeloid subsets were dependent on CD4+ T cells and GM-CSF. Transcriptomic and gene ontology analyses of CD64+MHCII+ and CD64+MHCII- macrophages revealed 89 differentially expressed genes, including genes involved in T cell proliferation and differentiation pathways. Depletion of phagocytes, including CD64+MHCII+ macrophages, from CHIKV-infected mice reduced disease pathology, demonstrating that these cells play a pro-inflammatory role in CHIKV infection. Together, these results highlight the synergistic dynamics of immune cell crosstalk in driving CHIKV immunopathogenesis. This study provides new insights in the disease mechanism and offers opportunities for development of novel anti-CHIKV therapeutics. Synopsis: Activated CD64+MHCII+ macrophages are present in the joint-footpad during CHIKV infection and participate in a pathogenic immune crosstalk with CD4+ T cells to drive immunopathogenesis. CD64+MHCII+ macrophages could be an alternative host-directed therapeutic target against CHIKV infection. Mass cytometry reveals the presence of CD64+MHCII+ macrophages in the CHIKV-infected joint-footpad. IFNγ and GM-CSF secreted by CD4+ T cells are two mediators capable of regulating the levels of CD64+MHCII+ macrophages in CHIKV-infected joints. In vivo depletion of GM-CSF reduces CHIKV disease severity. CD64+MHCII+ macrophages are involved in multiple T-cell-related pathways as revealed by RNAseq analyses. CD64+MHCII+ macrophages are potential novel targets for the future development of anti-CHIKV therapeutics. Activated CD64+MHCII+ macrophages are present in the joint-footpad during CHIKV infection and participate in a pathogenic immune crosstalk with CD4+ T cells to drive immunopathogenesis. CD64+MHCII+ macrophages could be an alternative host-directed therapeutic target against CHIKV infection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant

Author

Tay, Matthew Zirui, primary, Goh, Yun Shan, additional, Fong, Siew-Wai, additional, Chang, Zi Wei, additional, Rouers, Angeline, additional, Wong, Nathan, additional, Torres-Ruesta, Anthony, additional, Huang, Yuling, additional, Selvam, Sooriya Kannan, additional, Hor, Pei Xiang, additional, Loh, Chiew Yee, additional, Wang, Bei, additional, Mohd Salleh, Siti Nazihah, additional, Ngoh, Eve Zi Xian, additional, Lee, Raphael Tze Chuen, additional, Neo, Vanessa, additional, Kam, Isaac Kai Jie, additional, Poh, Xuan Ying, additional, Rao, Suma, additional, Chia, Po Ying, additional, Ong, Sean W.X., additional, Lee, Tau Hong, additional, Lim, Clarissa, additional, Teo, Jefanie, additional, Maurer-Stroh, Sebastian, additional, Wang, Cheng-I, additional, Leo, Yee-Sin, additional, Lin, Raymond Tzer Pin, additional, Lye, David C., additional, Young, Barnaby Edward, additional, Ng, Lisa F.P., additional, and Renia, Laurent, additional

Published
2023
Full Text
View/download PDF

22. Employment of a high throughput functional assay to define the critical factors that influence vaccine induced cross-variant neutralizing antibodies for SARS-CoV-2.

Author

Gu, Yue, Shunmuganathan, Bhuvaneshwari, Qian, Xinlei, Gupta, Rashi, Tan, Rebecca S. W., Kozma, Mary, Purushotorman, Kiren, Murali, Tanusya M., Tan, Nikki Y. J., Preiser, Peter R., Lescar, Julien, Nasir, Haziq, Somani, Jyoti, Tambyah, Paul A., Fong, Siew-Wai, Amrun, Siti Naqiah, Goh, Yun-Shan, Tay, Matthew Zi-Rui, Rouers, Angeline, and Chang, Zi Wei

Subjects
SARS-CoV-2 Omicron variant, IMMUNOGLOBULINS, SARS-CoV-2, ANTIBODY formation, MONOCLONAL antibodies, VIRAL antibodies, ANTIBODY titer
Abstract

The scale and duration of neutralizing antibody responses targeting SARS-CoV-2 viral variants represents a critically important serological parameter that predicts protective immunity for COVID-19. In this study, we describe the development and employment of a new functional assay that measures neutralizing antibodies for SARS-CoV-2 and present longitudinal data illustrating the impact of age, sex and comorbidities on the kinetics and strength of vaccine-induced antibody responses for key variants in an Asian volunteer cohort. We also present an accurate quantitation of serological responses for SARS-CoV-2 that exploits a unique set of in-house, recombinant human monoclonal antibodies targeting the viral Spike and nucleocapsid proteins and demonstrate a reduction in neutralizing antibody titres across all groups 6 months post-vaccination. We also observe a marked reduction in the serological binding activity and neutralizing responses targeting recently newly emerged Omicron variants including XBB 1.5 and highlight a significant increase in cross-protective neutralizing antibody responses following a third dose (boost) of vaccine. These data illustrate how key virological factors such as immune escape mutations combined with host demographic factors such as age and sex of the vaccinated individual influence the strength and duration of cross-protective serological immunity for COVID-19. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Mosquito Salivary Sialokinin Suppresses Monocyte Activation and Dampens Chikungunya-Induced Inflammation Through a Neurokinin Receptor-Associated Pathway

Author

Fong, Siew‐Wai, primary, Tan, Jeslin J.L., additional, Sridhar, Vaishnavi, additional, Amrun, Siti Naqiah, additional, Neo, Vanessa Kexin, additional, Wong, Nathan, additional, Lee, Bernett Teck Kwong, additional, Chan, Yi-Hao, additional, Torres-Ruesta, Anthony, additional, Chee, Rhonda S.L., additional, Chua, Tze-Kwang, additional, Carissimo, Guillaume, additional, Lum, Fok-Moon, additional, Kini, R. Manjunatha, additional, and Ng, Lisa F.P., additional

Published
2023
Full Text
View/download PDF

24. Efficient recall of SARS‐CoV‐2 variant‐reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters

Author

Rouers, Angeline, Wong, Nathan, Goh, Yun Shan, Torres-Ruesta, Anthony, Tay, Matthew Zirui, Chang, Zi Wei, Fong, Siew-Wai, Neo, Vanessa, Kam, Isaac Kai Jie, Yeo, Nicholas Kim-Wah, Huang, Yuling, Loh, Chiew Yee, Hor, Pei Xiang, Wong, Joel Xu En, Tan, Yong Jie, Macary, Paul A., Qian, Xinlei, Bei, Wang, Ngoh, Eve Zi Xian, Salleh, Siti Nazihah Mohd, Wang, Cheng-I, Poh, Xuan Ying, Rao, Suma, Chia, Po Ying, Ong, Sean W. X., Lee, Tau Hong, Lin, Ray J. H., Lim, Clarissa, Teo, Jefanie, Ren, Ee Chee, Lye, David C., Young, Barnaby Edward, Ng, Lisa F. P., Renia, Laurent, Lee Kong Chian School of Medicine (LKCMedicine), School of Biological Sciences, National Centre for Infectious Diseases, Tan Tock Seng Hospital, and A*STAR Infectious Diseases Labs

Subjects
Infectious Diseases, B Cell, Virology, Humoral Immunity, Medicine [Science]
Abstract

Waning antibody levels against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the emergence of variants of concern highlight the need for booster vaccinations. This is particularly important for the elderly population, who are at a higher risk of developing severe coronavirus disease 2019 (COVID-19) disease. While studies have shown increased antibody responses following booster vaccination, understanding the changes in T and B cell compartments induced by a third vaccine dose remains limited. We analyzed the humoral and cellular responses in subjects who received either a homologous messenger RNA(mRNA) booster vaccine (BNT162b2 + BNT162b2 + BNT162b2; ''BBB") or a heterologous mRNA booster vaccine (BNT162b2 + BNT162b2 + mRNA-1273; ''BBM") at Day 0 (prebooster), Day 7, and Day 28 (postbooster). Compared with BBB, elderly individuals (≥60 years old) who received the BBM vaccination regimen display higher levels of neutralizing antibodies against the Wuhan and Delta strains along with a higher boost in immunoglobulin G memory B cells, particularly against the Omicron variant. Circulating T helper type 1(Th1), Th2, Th17, and T follicular helper responses were also increased in elderly individuals given the BBM regimen. While mRNA vaccines increase antibody, T cell, and B cell responses against SARS-CoV-2 1 month after receiving the third dose booster, the efficacy of the booster vaccine strategies may vary depending on age group and regimen combination. Agency for Science, Technology and Research (A*STAR) National Medical Research Council (NMRC) Submitted/Accepted version This study was supported by Biomedical Research Council, A*CRUSE (Vaccine monitoring project), A*ccelerate GAP‐funded project (ACCL/19‐GAP064‐R20H‐H) from Agency of Science, Technology and Research (A*STAR), Singapore National Medical Research Council COVID‐19 Research Fund (COVID19RF‐001; COVID19RF‐007; COVID19RF‐0008; COVID19RF‐060; and OFLCG19May‐0034), U.S. Food and Drug Administration (#75F40120C00085), and A*STAR COVID‐19 Research funding (H/20/04/g1/006).

Published
2022
Full Text
View/download PDF

25. Conserved longitudinal alterations of anti-S-protein IgG subclasses in disease progression in initial ancestral Wuhan and vaccine breakthrough Delta infections

Author

Goh, Yun Shan, primary, Fong, Siew-Wai, additional, Hor, Pei Xiang, additional, Amrun, Siti Naqiah, additional, Lee, Cheryl Yi-Pin, additional, Young, Barnaby Edward, additional, Chia, Po Ying, additional, Tambyah, Paul A., additional, Kalimuddin, Shirin, additional, Pada, Surinder, additional, Tan, Seow-Yen, additional, Sun, Louisa Jin, additional, Chen, Mark I-Cheng, additional, Leo, Yee-Sin, additional, Lye, David C., additional, Ng, Lisa F. P., additional, and Renia, Laurent, additional

Published
2022
Full Text
View/download PDF

27. Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID‐19) resolves 2 years after infection.

Author

Fong, Siew‐Wai, Goh, Yun Shan, Torres‐Ruesta, Anthony, Chang, Zi Wei, Chan, Yi‐Hao, Neo, Vanessa Kexin, Lee, Bernett, Duan, Kaibo, Amrun, Siti Naqiah, Yeo, Nicholas Kim‐Wah, Chen, Hsiuyi V., Tay, Matthew Zirui, Carissimo, Guillaume, Tan, Seow Yen, Leo, Yee‐Sin, Lye, David C., Renia, Laurent, Young, Barnaby Edward, and Ng, Lisa F. P.

Subjects
SARS-CoV-2, COVID-19, CORONAVIRUS diseases
Abstract

Long‐term complications from coronavirus disease 2019 (COVID‐19) are concerning, as survivors can develop subclinical multiorgan dysfunction. It is unknown if such complications are due to prolonged inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination may reduce sequela. We conducted a prospective longitudinal study on hospitalized patients over 24 months. Clinical symptoms were collected by self‐reporting during follow‐up, along with blood samples for quantification of inflammatory markers and immune cell frequencies. All patients were given one dose of mRNA vaccine at 12−16 months. Their immune profiles at 12 and 24 months were compared. Approximately 37% and 39% of our patients reported post‐COVID‐19 symptoms at 12 and 24 months, respectively. The proportion of symptomatic patients with more than one symptom decreased from 69% at 12 months to 56% at 24 months. Longitudinal cytokine profiling revealed a cluster of individuals with persistently high inflammatory cytokine levels 12 months after infection. Patients with prolonged inflammation showed elevated terminally differentiated memory T cells in their blood; 54% had symptoms at 12 months. The majority of inflammatory markers and dysregulated immune cells in vaccinated patients recovered to a healthy baseline at 24 months, even though symptoms persisted. Post‐COVID‐19 symptoms can linger for 2 years after the initial infection and are associated with prolonged inflammation. Prolonged inflammation in hospitalized patients resolves after 2 years. We define a set of analytes associated with persistent inflammation and presence of symptoms, which could be useful biomarkers for identifying and monitoring high‐risk survivors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial

Author

Poh, Xuan Ying, primary, Tan, Chee Wah, additional, Lee, I Russel, additional, Chavatte, Jean-Marc, additional, Fong, Siew-Wai, additional, Prince, Tessa, additional, Hartley, Catherine, additional, Yeoh, Aileen Y Y, additional, Rao, Suma, additional, Chia, Po Ying, additional, Ong, Sean W X, additional, Lee, Tau Hong, additional, Sadarangani, Sapna P, additional, Lin, Ray J H, additional, Lim, Clarissa, additional, Teo, Jefanie, additional, Lim, Daniel R X, additional, Chia, Wanni, additional, Hiscox, Julian A, additional, Ng, Lisa F P, additional, Ren, Ee Chee, additional, Lin, Raymond T P, additional, Renia, Laurent, additional, Lye, David Chien, additional, Wang, Lin-Fa, additional, and Young, Barnaby E, additional

Published
2022
Full Text
View/download PDF

29. Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity

Author

Young, Barnaby E, Ong, Sean W X, Ng, Lisa F P, Anderson, Danielle E, Chia, Wan Ni, Chia, Po Ying, Ang, Li Wei, Mak, Tze-Minn, Kalimuddin, Shirin, Chai, Louis Yi Ann, Pada, Surinder, Tan, Seow Yen, Sun, Louisa, Parthasarathy, Purnima, Fong, Siew-Wai, Chan, Yi-Hao, Tan, Chee Wah, Lee, Bernett, Rötzschke, Olaf, Ding, Ying, Tambyah, Paul, Low, Jenny G H, Cui, Lin, Barkham, Timothy, Lin, Raymond Tzer Pin, Leo, Yee-Sin, Renia, Laurent, Wang, Lin-Fa, Lye, David Chien, Lim, Poh Lian, Peng Ang, Brenda Sze, Lee, Cheng Chuan, U Lee, Lawrence Soon, Ling, Li Min, Ng, Oon Tek, Chan, Monica, Marimuthu, Kalisvar, Vasoo, Shawn, Wong, Chen Seong, Lee, Tau Hong, Sadarangani, Sapna, Lin, Ray Junhao, Sadasiv, Mucheli Sharavan, Ling Ng, Deborah Hee, Choy, Chiaw Yee, En Tan, Glorijoy Shi, Tan, Yu Kit, Sutjipto, Stephanie, Lee, Pei Hua, Tay, Jun Yang, Yeo, Tsin Wen, Khoo, Bo Yan, Tay, Woo Chiao, Ng, Gabrielle, Mah, Yun Yuan, Tan, Wilnard, De, Partha Pratim, Pooja, Rao, Chia, Jonathan W Z, Constance Chen, Yuan Yi, Mendis, Shehara, Toh, Boon Kiat, Choon Fong, Raymond Kok, Lin Oh, Helen May, Fong Chien, Jaime Mei, Shafi, Humaira, Cheong, Hau Yiang, Tan, Thean Yen, Tan, Thuan Tong, Tan, Ban Hock, Wijaya, Limin, Venkatachalam, Indumathi, Chua, Ying Ying, Zhi Cherng, Benjamin Pei, Zi Chan, Yvonne Fu, Wong, Hei Man, Thien, Siew Yee, Meng Goh, Kenneth Choon, Ling Tan, Shireen Yan, Ean Oon, Lynette Lin, Chan, Kian Sing, Lin, Li, Gin Chan, Douglas Su, Ooi, Say Tat, Narayana, Deepak Rama, Somani, Jyoti, Ling Oon, Jolene Ee, Yan, Gabriel Zherong, Allen, David Michael, Jureen, Roland, Yan, Benedict, Foo, Randy, Kang, Adrian, Sivalingam, Velraj, How, Wilson, Fernandez, Norman Leo, Yeo, Nicholas Kim-Wah, Chee, Rhonda Sin-Ling, Amrun, Siti Naqiah, Lee Kong Chian School of Medicine (LKCMedicine), National Centre for Infectious Diseases, Tan Tock Seng Hospital, Yong Loo Lin School of Medicine, NUS, and Saw Swee Hock School of Public Health, NUS

Subjects
0301 basic medicine, Microbiology (medical), biology, Viral culture, business.industry, 030106 microbiology, COVID-19, medicine.disease, 03 medical and health sciences, Pneumonia, 0302 clinical medicine, Infectious Diseases, Immune system, Immunoglobulin M, Viral pneumonia, Immunology, Severity of illness, medicine, biology.protein, Cytokines, Medicine [Science], 030212 general & internal medicine, Seroconversion, Antibody, business
Abstract

Background Key knowledge gaps remain in the understanding of viral dynamics and immune response of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Methods We evaluated these characteristics and established their association with clinical severity in a prospective observational cohort study of 100 patients with PCR-confirmed SARS-CoV-2 infection (mean age, 46 years; 56% male; 38% with comorbidities). Respiratory samples (n = 74) were collected for viral culture, serum samples for measurement of IgM/IgG levels (n = 30), and plasma samples for levels of inflammatory cytokines and chemokines (n = 81). Disease severity was correlated with results from viral culture, serologic testing, and immune markers. Results Fifty-seven (57%) patients developed viral pneumonia, of whom 20 (20%) required supplemental oxygen, including 12 (12%) with invasive mechanical ventilation. Viral culture from respiratory samples was positive for 19 of 74 patients (26%). No virus was isolated when the PCR cycle threshold (Ct) value was >30 or >14 days after symptom onset. Seroconversion occurred at a median (IQR) of 12.5 (9–18) days for IgM and 15.0 (12–20) days for IgG; 54/62 patients (87.1%) sampled at day 14 or later seroconverted. Severe infections were associated with earlier seroconversion and higher peak IgM and IgG levels. Levels of IP-10, HGF, IL-6, MCP-1, MIP-1α, IL-12p70, IL-18, VEGF-A, PDGF-BB, and IL-1RA significantly correlated with disease severity. Conclusions We found virus viability was associated with lower PCR Ct value in early illness. A stronger antibody response was associated with disease severity. The overactive proinflammatory immune signatures offer targets for host-directed immunotherapy, which should be evaluated in randomized controlled trials.

Published
2020
Full Text
View/download PDF

30. Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical Trial

Author

Poh, Xuan Ying, Tan, Chee Wah, Lee, I Russel, Chavatte, Jean-Marc, Fong, Siew-Wai, Prince, Tessa, Hartley, Catherine, Yeoh, Aileen Ying-Yan, Rao, Suma, Chia, Po Ying, Ong, Sean WX, Lee, Tau Hong, Sadarangani, Sapna P, Lin, Ray JH, Lim, Clarissa, Teo, Jefanie, Lim, Daniel RX, Chia, Wanni, Hiscox, Julian A, Ng, Lisa FP, Ren, Ee Chee, Lin, Raymond TP, Renia, Laurent, Lye, David Chien, Wang, Lin-Fa, and Young, Barnaby E

Subjects
History, Polymers and Plastics, Business and International Management, Industrial and Manufacturing Engineering
Abstract

Background Waning antibody levels post-vaccination and the emergence of variants of concern (VOCs) capable of evading protective immunity has raised the need for booster vaccinations. However, which combination of COVID-19 vaccines offers the strongest immune response against Omicron variant is unknown. Methods This randomized, subject-blinded, controlled trial assessed the reactogenicity and immunogenicity of different COVID-19 vaccine booster combinations. 100 BNT162b2-vaccinated individuals were enrolled and randomized 1: 1 to either homologous (BNT162b2 + BNT162b2 + BNT162b2; ‘BBB’) or heterologous mRNA booster vaccine (BNT162b2 + BNT162b2 + mRNA-1273; ‘BBM’). Primary endpoint was the level of neutralizing antibodies against SARS-CoV-2 wild-type and VOCs at Day 28. Results 51 participants were allocated to BBB and 49 to BBM; 50 and 48 respectively were analyzed for safety and immunogenicity outcomes. At Day 28 post-boost, mean SARS-CoV-2 spike antibody titers were lower with BBB (22,382 IU/mL 95% CI, 18,210 to 27,517) vs BBM (29,751 IU/mL 95% CI, 25,281 to 35,011, p = 0.034) as was the median level of neutralizing antibodies: BBB 99.0% (IQR 97.9 to 99.3%) vs BBM 99.3% (IQR 98.8 to 99.5%, p = 0.021). On sub-group analysis, significant differences in mean spike antibody titer and live Omicron neutralization titer was only observed in older adults. Median surrogate neutralizing antibody level against all VOCs was also significantly higher with BBM in older adults, and against Omicron was BBB 72.8% (IQR 54.0 to 84.7%) vs BBM 84.3% (IQR 78.1 to 88.7%, p = 0.0073). Both vaccines were well tolerated. Conclusions Heterologous mRNA-1273 booster vaccination induced a stronger neutralizing response against the Omicron variant in older individuals compared with homologous BNT123b2.

Published
2022
Full Text
View/download PDF

31. Comparison of the clinical features, viral shedding and immune response in vaccine breakthrough infection by the Omicron and Delta variants

Author

Young, Barnaby, primary, Fong, Siew-Wai, additional, Chang, Zi Wei, additional, Tan, Kai Sen, additional, Rouers, Angeline, additional, Goh, Yun Shan, additional, Tay, Douglas Jie Wen, additional, Ong, Sean W. X., additional, Hao, Ying, additional, Chua, Siang Li, additional, Chavatte, Jean-Marc, additional, Cui, Lin, additional, Tay, Matthew, additional, Lin, Raymond Tzer Pin, additional, Renia, Laurent, additional, Leo, Yee-Sin, additional, Chu, Justin Jang Hann, additional, Lye, David, additional, and Ng, Lisa Fong Poh, additional

Published
2022
Full Text
View/download PDF

32. Malaria abrogates O’nyong–nyong virus pathologies by restricting virus infection in nonimmune cells

Author

Torres-Ruesta, Anthony, primary, Teo, Teck-Hui, additional, Chan, Yi-Hao, additional, Amrun, Siti Naqiah, additional, Yeo, Nicholas Kim-Wah, additional, Lee, Cheryl Yi-Pin, additional, Nguee, Samantha Yee-Teng, additional, Tay, Matthew Zirui, additional, Nosten, Francois, additional, Fong, Siew-Wai, additional, Lum, Fok-Moon, additional, Carissimo, Guillaume, additional, Renia, Laurent, additional, and Ng, Lisa FP, additional

Published
2022
Full Text
View/download PDF

33. Prolonged Inflammation in COVID-19 Survivors Resolves 2 Years After Coronavirus Disease 2019 (COVID-19)

Author

Fong, Siew‐Wai, primary, Goh, Yun Shan, additional, Torres-Ruesta, Anthony, additional, Chang, Zi Wei, additional, Chan, Yi-Hao, additional, Neo, Vanessa Kexin, additional, Lee, Bernett, additional, Duan, Kaibo, additional, Amrun, Siti Naqiah, additional, Yeo, Nicholas Kim‐Wah, additional, Tay, Matthew Zirui, additional, Carissimo, Guillaume, additional, Group, NCID Study, additional, Tan, Seow-Yen, additional, Leo, Yee-Sin, additional, Lye, David Chien, additional, Renia, Laurent, additional, Young, Barnaby E., additional, and Ng, Lisa F.P., additional

Published
2022
Full Text
View/download PDF

34. Comparison of the Clinical Features, Viral Shedding and Immune Response in Vaccine Breakthrough Infection by the Omicron and Delta Variants

Author

Tham, Sai Meng, primary, Fong, Siew‐Wai, additional, Chang, Zi-Wei, additional, Tan, Kai Sen, additional, Rouers, Angeline, additional, Goh, Yun Shan, additional, Tay, Douglas Jie Wen, additional, Ong, Sean Wei Xiang, additional, Hao, Ying, additional, Chua, Siang Li, additional, Chavatte, Jean-Marc, additional, Cui, Lin, additional, Tay, Matthew Zirui, additional, Lin, Raymond Tzer Pin, additional, Renia, Laurent, additional, Leo, Yee-Sin, additional, Chu, Justin Jang Hann, additional, Lye, David Chien, additional, Ng, Lisa F.P., additional, Young, Barnaby E., additional, and Cohort Study Group, PROTECT, additional

Published
2022
Full Text
View/download PDF

36. Efficient recall of SARS‐CoV‐2 variant‐reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters.

Author

Rouers, Angeline, Wong, Nathan, Goh, Yun Shan, Torres‐Ruesta, Anthony, Tay, Matthew Zirui, Chang, Zi Wei, Fong, Siew‐Wai, Neo, Vanessa, Kam, Isaac Kai Jie, Yeo, Nicholas Kim‐Wah, Huang, Yuling, Loh, Chiew Yee, Hor, Pei Xiang, Wong, Joel Xu En, Tan, Yong Jie, Macary, Paul A., Qian, Xinlei, Bei, Wang, Ngoh, Eve Zi Xian, and Salleh, Siti Nazihah Mohd

Subjects
SARS-CoV-2, BOOSTER vaccines, B cells, T cells, COVID-19
Abstract

Waning antibody levels against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and the emergence of variants of concern highlight the need for booster vaccinations. This is particularly important for the elderly population, who are at a higher risk of developing severe coronavirus disease 2019 (COVID‐19) disease. While studies have shown increased antibody responses following booster vaccination, understanding the changes in T and B cell compartments induced by a third vaccine dose remains limited. We analyzed the humoral and cellular responses in subjects who received either a homologous messenger RNA(mRNA) booster vaccine (BNT162b2 + BNT162b2 + BNT162b2; "BBB") or a heterologous mRNA booster vaccine (BNT162b2 + BNT162b2 + mRNA‐1273; "BBM") at Day 0 (prebooster), Day 7, and Day 28 (postbooster). Compared with BBB, elderly individuals (≥60 years old) who received the BBM vaccination regimen display higher levels of neutralizing antibodies against the Wuhan and Delta strains along with a higher boost in immunoglobulin G memory B cells, particularly against the Omicron variant. Circulating T helper type 1(Th1), Th2, Th17, and T follicular helper responses were also increased in elderly individuals given the BBM regimen. While mRNA vaccines increase antibody, T cell, and B cell responses against SARS‐CoV‐2 1 month after receiving the third dose booster, the efficacy of the booster vaccine strategies may vary depending on age group and regimen combination. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month

Author

Renia, Laurent, primary, Goh, Yun Shan, additional, Rouers, Angeline, additional, Bert, Nina Le, additional, Chia, Wan Ni, additional, Chavatte, Jean Marc, additional, Fong, Siew-Wai, additional, Chang, Zi Wei, additional, Zhuo, Ziyi, additional, Tay, Matthew, additional, Chan, Yi Hao, additional, Tan, Chee Wha, additional, Yeo, Nicholas, additional, Amrun, Siti Naqiah, additional, Huang, Yuling, additional, Hor, Pei Xiang, additional, Loh, Chiew Yeee, additional, Carissimo, Guillaume, additional, Dowla, Samanzer, additional, Lim, Alicia, additional, Zhang, Jinyan, additional, Ding, Ying, additional, Pada, Surinder, additional, Sun, Louisa, additional, Somani, Jyoti, additional, Lee, Eng Sing, additional, Lin, Raymond, additional, Ong, Desmond, additional, Leo, Yee-Sin, additional, Wang, Lin-Fa, additional, Lye, David, additional, Bertoletti, Antonio, additional, Ren, Ee Chee, additional, Young, Barnaby, additional, and Ng, Lisa Fong Poh, additional

Published
2021
Full Text
View/download PDF

38. Correction to: Robust Virus‐Specific Adaptive Immunity in COVID‐19 Patients with SARS‐CoV‐2 Δ382 Variant Infection

Author

Fong, Siew‐Wai, primary, Yeo, Nicholas Kim‐Wah, additional, Chan, Yi‐Hao, additional, Goh, Yun Shan, additional, Amrun, Siti Naqiah, additional, Ang, Nicholas, additional, Rajapakse, Menaka Priyadharsani, additional, Lum, Josephine, additional, Foo, Shihui, additional, Lee, Cheryl Yi‐Pin, additional, Carissimo, Guillaume, additional, Chee, Rhonda Sin‐Ling, additional, Torres‐Ruesta, Anthony, additional, Tay, Matthew Zirui, additional, Chang, Zi Wei, additional, Poh, Chek Meng, additional, Young, Barnaby Edward, additional, Tambyah, Paul A., additional, Kalimuddin, Shirin, additional, Leo, Yee‐Sin, additional, Lye, David C., additional, Lee, Bernett, additional, Biswas, Subhra, additional, Howland, Shanshan Wu, additional, Renia, Laurent, additional, and Ng, Lisa F. P., additional

Published
2021
Full Text
View/download PDF

39. Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals

Author

Lim, Jackwee, primary, Puan, Kia Joo, additional, Wang, Liang Wei, additional, Teng, Karen Wei Weng, additional, Loh, Chiew Yee, additional, Tan, Kim Peng, additional, Carissimo, Guillaume, additional, Chan, Yi-Hao, additional, Poh, Chek Meng, additional, Lee, Cheryl Yi-Pin, additional, Fong, Siew-Wai, additional, Yeo, Nicholas Kim-Wah, additional, Chee, Rhonda Sin-Ling, additional, Amrun, Siti Naqiah, additional, Chang, Zi Wei, additional, Tay, Matthew Zirui, additional, Torres-Ruesta, Anthony, additional, Leo Fernandez, Norman, additional, How, Wilson, additional, Andiappan, Anand Kumar, additional, Lee, Wendy, additional, Duan, Kaibo, additional, Tan, Seow-Yen, additional, Yan, Gabriel, additional, Kalimuddin, Shirin, additional, Lye, David Chien, additional, Leo, Yee-Sin, additional, Ong, Sean W. X., additional, Young, Barnaby E., additional, Renia, Laurent, additional, Ng, Lisa F. P., additional, Lee, Bernett, additional, and Rötzschke, Olaf, additional

Published
2021
Full Text
View/download PDF

40. Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Δ382 Variant Infection

Author

Fong, Siew-Wai, primary, Yeo, Nicholas Kim-Wah, additional, Chan, Yi-Hao, additional, Goh, Yun Shan, additional, Amrun, Siti Naqiah, additional, Ang, Nicholas, additional, Rajapakse, Menaka Priyadharsani, additional, Lum, Josephine, additional, Foo, Shihui, additional, Lee, Cheryl Yi-Pin, additional, Carissimo, Guillaume, additional, Chee, Rhonda Sin-Ling, additional, Torres-Ruesta, Anthony, additional, Tay, Matthew Zirui, additional, Chang, Zi Wei, additional, Poh, Chek Meng, additional, Young, Barnaby Edward, additional, Tambyah, Paul A., additional, Kalimuddin, Shirin, additional, Leo, Yee-Sin, additional, Lye, David C., additional, Lee, Bernett, additional, Biswas, Subhra, additional, Howland, Shanshan Wu, additional, Renia, Laurent, additional, and Ng, Lisa F. P., additional

Published
2021
Full Text
View/download PDF

41. Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians

Author

Wang, Bei, primary, Goh, Yun Shan, additional, Fong, Siew-Wai, additional, Young, Barnaby Edward, additional, Ngoh, Eve Zi Xian, additional, Chavatte, Jean-Marc, additional, Salleh, Siti Nazihah Mohd, additional, Yeo, Nicholas Kim-Wah, additional, Amrun, Siti Naqiah, additional, Hor, Pei Xiang, additional, Loh, Chiew Yee, additional, Lee, Chia Yin, additional, Chan, Yi-Hao, additional, Chang, Zi Wei, additional, Tay, Matthew Zirui, additional, Rouers, Angeline, additional, Torres-Ruesta, Anthony, additional, Carissimo, Guillaume, additional, Soh, Mun Kuen, additional, Lee, Raphael Tze Chuen, additional, Xu, Yani, additional, Pada, Surinder, additional, Lin, Raymond Tzer Pin, additional, Leo, Yee-Sin, additional, Lye, David C., additional, Maurer-Stroh, Sebastian, additional, Ng, Lisa F.P., additional, Renia, Laurent, additional, and Wang, Cheng-I, additional

Published
2021
Full Text
View/download PDF

43. Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir

Author

Chan, Yi-Hao, primary, Young, Barnaby E., additional, Fong, Siew-Wai, additional, Ding, Ying, additional, Goh, Yun Shan, additional, Chee, Rhonda Sin-Ling, additional, Tan, Seow-Yen, additional, Kalimuddin, Shirin, additional, Tambyah, Paul A., additional, Leo, Yee-Sin, additional, Ng, Lisa F. P., additional, Lye, David Chien, additional, and Renia, Laurent, additional

Published
2021
Full Text
View/download PDF

44. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

Author

Chia, Wan Ni, primary, Zhu, Feng, additional, Ong, Sean Wei Xiang, additional, Young, Barnaby Edward, additional, Fong, Siew-Wai, additional, Le Bert, Nina, additional, Tan, Chee Wah, additional, Tiu, Charles, additional, Zhang, Jinyan, additional, Tan, Seow Yen, additional, Pada, Surinder, additional, Chan, Yi-Hao, additional, Tham, Christine Y L, additional, Kunasegaran, Kamini, additional, Chen, Mark I-C, additional, Low, Jenny G H, additional, Leo, Yee-Sin, additional, Renia, Laurent, additional, Bertoletti, Antonio, additional, Ng, Lisa F P, additional, Lye, David Chien, additional, and Wang, Lin-Fa, additional

Published
2021
Full Text
View/download PDF

45. Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine.

Author

Goh, Yun Shan, Fong, Siew‐Wai, Rouers, Angeline, Chang, Zi Wei, Tay, Matthew Zirui, Chavatte, Jean‐Marc, Zhuo, Nicole Ziyi, Hor, Pei Xiang, Loh, Chiew Yee, Huang, Yuling, Wong, Joel Xu En, Tan, Yong Jie, Lim, Daniel Rui Xiang, Wang, Bei, Ngoh, Eve Zi Xian, Salleh, Siti Nazihah Mohd, Lee, Raphael Tze Chuen, Pada, Surinder, Sun, Louisa Jin, and Ong, Desmond Luan Seng

Subjects
*BOOSTER vaccines, *COVID-19 vaccines, *SARS-CoV-2 Omicron variant, *MESSENGER RNA, *VACCINATION
Abstract

Objective: Despite the high vaccine efficacy of mRNA COVID‐19 vaccines, there are individuals who developed excessive reactogenic and/or allergic responses after the first mRNA dose and were considered ineligible for further mRNA doses. CoronaVac, an inactivated SARS‐CoV‐2 vaccine, is recommended in Singapore as an alternative. Methods: Individuals, ineligible for further mRNA vaccines (BNT162b2 or mRNA‐1273) because of excessive reactive responses to prime mRNA vaccination, were recruited and offered two doses of CoronaVac as booster vaccination 38–224 days post their mRNA vaccine dose. Individuals who did not develop any excessive reactive responses after the prime mRNA vaccination were also recruited and given another mRNA vaccine as booster vaccination. Blood samples were collected at days 0, 21 and 90 post first CoronaVac dose and mRNA dose, respectively, for analysis. Results: We showed that two CoronaVac booster doses induced specific immunity in these mRNA vaccine‐primed individuals. Although the spike‐specific antibody response was lower, their memory B cell response against the receptor‐binding domain (RBD) of the spike protein was similar, compared with individuals who received two BNT162b2 injections. The spike‐specific memory T cell response also increased following CoronaVac booster doses. However, specific immunity against the Omicron variant was low, similar to individuals with two BNT162b2 doses. Conclusion: Our findings showed that while mRNA vaccine‐primed individuals can opt for two subsequent doses of CoronaVac, an additional dose may be necessary to achieve protection, especially against newly emerging immune escape variants such as Omicron. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Dynamic Alterations of Anti-S-Protein Igg Subclasses and of Th1/Th2 Responses are Hallmarks of Acute Severe COVID-19 Disease

Author

Goh, Yun Shan, primary, Fong, Siew-Wai, additional, Amrun, Siti Naqiah, additional, Lee, Cheryl, additional, Hor, Pei Xiang, additional, Young, Barnaby, additional, Chia, Po Ying, additional, Tambyah, Paul, additional, Kalimuddin, Shirin, additional, Pada, Surinder, additional, Tan, Seow-Yen, additional, Sun, Louisa, additional, Chen, Mark, additional, Leo, Yee-Sin, additional, Lye, David, additional, Ng, Lisa, additional, and Renia, Laurent, additional

Published
2021
Full Text
View/download PDF

47. Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients

Author

Ong, Sean Wei Xiang, primary, Fong, Siew-Wai, additional, Young, Barnaby Edward, additional, Chan, Yi-Hao, additional, Lee, Bernett, additional, Amrun, Siti Naqiah, additional, Chee, Rhonda Sin-Ling, additional, Yeo, Nicholas Kim-Wah, additional, Tambyah, Paul, additional, Pada, Surinder, additional, Tan, Seow Yen, additional, Ding, Ying, additional, Renia, Laurent, additional, Leo, Yee-Sin, additional, Ng, Lisa F P, additional, and Lye, David Chien, additional

Published
2021
Full Text
View/download PDF

48. Viral dynamics and immune correlates of COVID-19 disease severity

Author

Young, Barnaby E, Ong, Sean W X, Ng, Lisa F P, Anderson, Danielle E, Chia, Wan Ni, Chia, Po Ying, Ang, Li Wei, Mak, Tze-Minn, Kalimuddin, Shirin, Chai, Louis Yi Ann, Pada, Surinder, Tan, Seow Yen, Sun, Louisa, Parthasarathy, Purnima, Fong, Siew-Wai, Chan, Yi-Hao, Tan, Chee Wah, Lee, Bernett, Rötzschke, Olaf, Ding, Ying, Tambyah, Paul, Low, Jenny G H, Cui, Lin, Barkham, Timothy, Lin, Raymond Tzer Pin, Leo, Yee-Sin, Renia, Laurent, Wang, Lin-Fa, and Lye, David Chien

Subjects
immunology, AcademicSubjects/MED00290, Severe acute respiratory syndrome-related coronavirus, SARS-CoV-2, Major Article, viral culture, COVID-19, serology, Humans, Antibodies, Viral, cytokines
Abstract

Background Key knowledge gaps remain in the understanding of viral dynamics and immune response of SARS-CoV-2 infection. Methods We evaluated these characteristics and established their association with clinical severity in a prospective observational cohort study of 100 patients with PCR-confirmed SARS-CoV-2 infection (mean age 46 years, 56% male, 38% with comorbidities). Respiratory samples (n=74) were collected for viral culture, serum samples for measurement of IgM/IgG levels (n=30), and plasma samples for levels of inflammatory cytokines and chemokines (n=81). Disease severity was correlated with results from viral culture, serologic testing, and immune markers. Results 57 (57%) patients developed viral pneumonia, of whom 20 (20%) required supplemental oxygen including 12 (12%) invasive mechanical ventilation. Viral culture from respiratory samples was positive for 19 of 74 patients (26%). No virus was isolated when the PCR cycle threshold (Ct) value was >30 or >14 days after symptom onset. Seroconversion occurred at a median of 12.5 days (IQR 9-18) for IgM and 15.0 days (IQR 12-20) for IgG; 54/62 patients (87.1%) sampled at day 14 or later seroconverted. Severe infections were associated with earlier seroconversion and higher peak IgM and IgG levels. Levels of IP-10, HGF, IL-6, MCP-1, MIP-1α, IL-12p70, IL-18, VEGF-A, PDGF-BB and IL-1RA significantly correlated with disease severity. Conclusion We found virus viability was associated with lower PCR Ct value in early illness. A stronger antibody response was associated with disease severity. The overactive proinflammatory immune signatures offers targets for host-directed immunotherapy which should be evaluated in randomised controlled trials.

Published
2020

49. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation

Author

Chioh, Florence WJ, primary, Fong, Siew-Wai, additional, Young, Barnaby E, additional, Wu, Kan-Xing, additional, Siau, Anthony, additional, Krishnan, Shuba, additional, Chan, Yi-Hao, additional, Carissimo, Guillaume, additional, Teo, Louis LY, additional, Gao, Fei, additional, Tan, Ru San, additional, Zhong, Liang, additional, Koh, Angela S, additional, Tan, Seow-Yen, additional, Tambyah, Paul A, additional, Renia, Laurent, additional, Ng, Lisa FP, additional, Lye, David C, additional, and Cheung, Christine, additional

Published
2021
Full Text
View/download PDF

50. Data-driven analysis of COVID-19 reveals specific severity patterns distinct from the temporal immune response

Author

Lim, Jackwee, primary, Puan, Kia Joo, additional, Wang, Liang Wei, additional, Weng Teng, Karen Wei, additional, Loh, Chiew Yee, additional, Tan, Kim Peng, additional, Carissimo, Guillaume, additional, Chan, Yi-Hao, additional, Poh, Chek Meng, additional, Lee, Cheryl Yi-Pin, additional, Fong, Siew-Wai, additional, Yeo, Nicholas Kim-Wah, additional, Chee, Rhonda Sin-Ling, additional, Amrun, Siti Naqiah, additional, Chang, Zi Wei, additional, Tay, Matthew Zirui, additional, Torres-Ruesta, Anthony, additional, Fernandez, Norman Leo, additional, How, Wilson, additional, Andiappan, Anand K., additional, Lee, Wendy, additional, Duan, Kaibo, additional, Tan, Seow-Yen, additional, Yan, Gabriel, additional, Kalimuddin, Shirin, additional, Lye, David Chien, additional, Leo, Yee-Sin, additional, Ong, Sean W. X., additional, Young, Barnaby E., additional, Renia, Laurent, additional, Ng, Lisa F.P., additional, Lee, Bernett, additional, and Rötzschke, Olaf, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results